In their study, they showed that SIRT1 promotes a beneficial metabolic effect through interaction with PPARγ, leading to insulin sensitization, and implied a therapeutic potential of TZD and SIRT1 agonist combination therapy for obesity [52]. Here, SIRT1 is linked to obesity due to melanocortin 4 receptor deficiency.